It is made available under a CC-BY-NC-ND 4.0 International license .

# 1 Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and

# 2 adolescents: a phase 3, randomized, placebo-controlled trial (PREVENT-19)

- 3 Germán Áñez,<sup>1</sup> Alice McGarry,<sup>1</sup> Wayne Woo,<sup>1</sup> Karen L. Kotloff,<sup>2</sup> Cynthia L. Gay,<sup>3</sup> Mingzhu Zhu,<sup>1</sup>
- 4 Shane Cloney-Clark,<sup>1</sup> Joy Nelson,<sup>1</sup> Haoua Dunbar,<sup>1</sup> Miranda R. Cai,<sup>1</sup> Iksung Cho,<sup>1</sup> Zhaohui
- 5 Cai,<sup>1</sup> Raj Kalkeri,<sup>1</sup> Joyce S. Plested,<sup>1</sup> Nita Patel,<sup>1</sup> Katherine Smith,<sup>1</sup> Anthony M. Marchese,<sup>1</sup>
- 6 Gregory M. Glenn,<sup>1</sup> Raburn M. Mallory,<sup>1</sup> Lisa M. Dunkle,<sup>1</sup> for the 2019CoVn-301 Study
- 7 Investigators
- <sup>8</sup> <sup>1</sup>Novavax, Inc., Gaithersburg, Maryland, USA
- <sup>9</sup> <sup>2</sup>Center for Vaccine Development and Global Health, University of Maryland School of Medicine,
- 10 Baltimore, Maryland, USA
- <sup>11</sup> <sup>3</sup>Institute for Global Health and Infectious Diseases, University of North Carolina School of
- 12 Medicine, Chapel Hill, North Carolina, USA
- 13

# 14 **Correspondence**:

- 15 Lisa M. Dunkle, MD
- 16 700 Quince Orchard Road., Gaithersburg, MD 20878
- 17 <u>ldunkle@novavax.com</u>
- 18 ORCID: 0009-0000-8856-3341
- 19

# 20 Abbreviations

- AE, adverse event; AESI, adverse event of special interest; ELISA, enzyme-linked
- 22 immunosorbent assay; hACE2-RBI, human angiotensin-converting enzyme-2 receptor binding
- 23 inhibition; GMEU, geometric mean ELISA unit; GMFR, geometric mean fold rise; GMT,
- 24 geometric mean titer; LLOQ, lower limit of quantification; MAAE, medically attended adverse
- event; nAb, neutralizing antibody; NP, nucleoprotein; PIMMC, potentially immune-mediated
- 26 medical condition; PP-IMM, per-protocol immunogenicity; rS, recombinant Spike; SAE, serious
- 27 adverse event; SCR, seroconversion rate; TEAE, treatment-emergent adverse event.
- 28
- 29 Article type: Original Research Article
- 30 Abstract word count: 298/300
- 31 Word count: 3767/5000
- 32 Figures/tables (10 limit): 4/1
- 33 **References:** 28/50

It is made available under a CC-BY-NC-ND 4.0 International license .

## 35 **ABSTRACT** [word count: 298/300]

#### 36 Background

- NVX-CoV2373, a recombinant SARS-CoV-2 spike (rS) protein vaccine with Matrix-M<sup>™</sup> adjuvant,
- has been authorized for use in adults and adolescents. PREVENT-19
- 39 (NCT04611802/2019nCoV-301), a pivotal phase 3, randomized, placebo-controlled trial
- 40 demonstrated robust efficacy of a primary, 2-dose series of NVX-CoV2373 against COVID-19.

#### 41 Methods

- 42 Protocol expansions to PREVENT-19 included enrollment of adolescents (aged 12 to <18
- 43 years) and administration of 3<sup>rd</sup> and 4<sup>th</sup> doses of NVX-CoV2373 to adults and adolescents.
- 44 Participants randomized 2:1 received NVX-CoV2373 or placebo 21 days apart; 3<sup>rd</sup> and 4<sup>th</sup> doses
- 45 were administered  $\geq$ 6 months after the preceding dose. Secondary and additional assessments
- 46 included post–3<sup>rd</sup>- and 4<sup>th</sup>-dose immune responses (neutralizing antibody [nAb], anti-rS lgG,
- 47 human angiotensin-converting enzyme-2-receptor binding inhibition [hACE2-RBI]) and
- response durability (post–3<sup>rd</sup> dose) to ancestral virus; cross-reactivity to Omicron subvariants;
- 49 safety; and reactogenicity.

#### 50 Results

- 51 Immune responses were observed against ancestral virus after two doses of NVX-CoV2373 but
- 52 not after placebo. In both adults and adolescents, additional doses of NVX-CoV2373 increased
- nAb titers, anti-rS IgG levels, and hACE2-RBI; durable responses were recorded 8 months post
- <sup>54</sup> 3<sup>rd</sup> dose. nAb responses post 3<sup>rd</sup> dose were noninferior to those post primary series. Cross-
- reactivity to BA.5 and BQ.1.1 variants was also observed, with anti-rS IgG levels post 3<sup>rd</sup> or 4<sup>th</sup>
- dose exceeding previously reported correlates of protection. Additional doses of NVX-CoV2373
- 57 were well tolerated, with no new safety signals.

#### 58 Conclusions

- 59 NVX-CoV2373 elicited robust and durable humoral immune responses to ancestral SARS-
- 60 CoV-2 as a 3<sup>rd</sup> and 4<sup>th</sup> dose after the primary series in adults and adolescents. Cross-reactivity
- to relevant variants provides insight into potential protection against antigenically related, but
- 62 shifted, viral strains. Additional doses of NVX-CoV2373 were well tolerated with no new safety
- 63 signals. These results support the utility of this vaccine platform and continued updates, based
- on currently circulating strains, to help effectively combat SARS-CoV-2 infection.
- 65 Keywords (3–8): COVID-19, vaccine, durability, reactogenicity, booster, adolescent

It is made available under a CC-BY-NC-ND 4.0 International license .

- 66 **Highlights** (3–5 bullets; 85 characters, including spaces, per bullet)
- NVX-CoV2373 elicits robust and durable humoral immune responses to SARS-CoV-2
   3<sup>rd</sup> and 4<sup>th</sup> subsequent homologous doses are immunogenic and well tolerated
   NVX-CoV2373 was cross-reactive to variants circulating at the time of this study
- 71

It is made available under a CC-BY-NC-ND 4.0 International license .

## 72 1. Introduction

96

73	NVX-CoV2373 is a recombinant spike (rS) protein prototype vaccine to ancestral SARS-CoV-2
74	with a saponin-based adjuvant (Matrix- $M^{TM}$ ) that was authorized for use in adults and
75	adolescents in the United States (US), and many other regions, for primary vaccination and
76	additional homologous or heterologous doses. <sup>1,2</sup> An updated version, NVX-CoV2601, contains
77	XBB.1.5 rS and was authorized in 2023–2024 for use in people aged ≥12 years. <sup>2,3</sup> In 2024, the
78	World Health Organization and US Centers for Disease Control and Prevention estimates
79	suggested that XBB.1.5-based COVID-19 vaccines were effective against symptomatic SARS-
80	CoV-2 infection, including cross protection. <sup>4,5</sup> Based on SARS-CoV-2 variant evolution, another
81	COVID-19 vaccine update was initiated for 2024–2025, targeting the JN.1-lineage, <sup>6</sup> resulting in
82	updated authorizations/approvals, <sup>7</sup> including for the Novavax COVID-19 vaccine. Despite the
83	availability of updated formulations, immunogenicity of repeated homologous prototype
84	vaccinations remains relevant in the context of cross-protection among variants and durability of
85	humoral immune responses.
86	Prefusion Protein Subunit Vaccine Efficacy Novavax Trial-COVID-19 (PREVENT-19),
87	was a pivotal phase 3, randomized, placebo-controlled, multicenter clinical trial of NVX-
88	CoV2373 conducted in ~30,000 adults in the US and Mexico (NCT04611802/2019nCoV-301).
89	The primary objective was met with 90% vaccine efficacy against mild, moderate, or severe
90	COVID-19.8 Additional analyses demonstrated 100% efficacy against moderate-to-severe
91	disease and hospitalization ≥7 days after the 2 <sup>nd</sup> dose. <sup>8,9</sup> No preliminary safety concerns were
92	raised, with a median 2-month safety follow-up.
93	A pediatric expansion was initiated in April 2021 to enroll adolescents (aged 12 to <18
94	years) in the US; preliminary safety, immunogenicity, and efficacy were demonstrated in an
95	interim report. <sup>10</sup> Additionally, to align with evolving public health recommendations, protocol

4

amendments allowed participants who completed an NVX-CoV2373 primary series to receive a

It is made available under a CC-BY-NC-ND 4.0 International license .

3<sup>rd</sup> dose and subsequent 4<sup>th</sup> dose. This report describes immunogenicity and safety results from
adults and adolescents enrolled in PREVENT-19, including outcomes from participants who
received additional doses of NVX-CoV2373. Immunogenicity against the ancestral strain and
cross-reactivity against viral variants predominant at the time of this report are included.

## 101 2. Methods

#### 102 2.1. Study design

Enrollment criteria for adult<sup>8</sup> and adolescent (aged 12 to <18 years)<sup>10</sup> participants were 103 described previously. Participants were randomized 2:1 to receive two intramuscular injections 104 105 of either NVX-CoV2373 or placebo 21 days apart (Figure S1). After accrual of safety data to 106 support Emergency Use Authorization, participants could opt in for the blinded crossover and 107 receive alternate treatment from their original randomization group. Adult participants in study 108 follow-up for  $\geq 6$  months ( $\geq 5$  months for adolescents) after receipt of the NVX-CoV2373 primary series were eligible for a  $3^{rd}$  dose (open label); a  $4^{th}$  dose was offered at select sites  $\geq 6$  months 109 110 later.

111 2.2. Objectives

112 Results of primary efficacy, initial safety, and some secondary objectives post primary series in adults and adolescents have been reported previously.<sup>8,10</sup> Final adult safety outcomes, as well 113 as updated immunogenicity and safety analyses post-primary series dosing and outcomes and 114 after 3<sup>rd</sup> and 4<sup>th</sup> doses in adults and adolescent participants are reported here. Secondary 115 116 immunogenicity objectives were neutralizing antibody (nAb) titers, serum IgG levels, and human 117 angiotensin-converting enzyme-2 (hACE2) receptor-binding inhibition (RBI) before and 14 days 118 after (day 35) the NVX-CoV2373 primary series. The 14-day timepoint for the primary series was used in this study based on timing in pivotal COVID-19 vaccine trials in the height of the 119 pandemic.<sup>8,11</sup> Immune responses 28 days after the 3<sup>rd</sup> and 4<sup>th</sup> doses and comparison of these to 120 the primary series responses were assessed. 121

It is made available under a CC-BY-NC-ND 4.0 International license .

Safety assessment included collection of solicited local and systemic reactogenicity for 7
days after each study dose and incidence and severity of unsolicited adverse events (AEs) for
28 days after each study dose. Overall safety included frequency and severity of treatmentrelated medically attended AEs (MAAEs), AEs of special interest (AESI), serious AEs (SAEs),
and death due to any cause throughout study follow-up.

127 2.3. Procedures

128 Participants received NVX-CoV2373 (5 µg SARS-CoV-2 rS protein and 50 µg Matrix-M

adjuvant) via a 0.5-mL intramuscular injection. Blood samples for measurement of serum

antibody responses were collected on day 0 (before the 1<sup>st</sup> dose), day 35 (14 days following the

131 2<sup>nd</sup> dose), and before and 28 days after the 3<sup>rd</sup> and 4<sup>th</sup> doses. Blood samples and nasal swabs

were obtained from participants before the primary series, 3<sup>rd</sup>, and 4<sup>th</sup> doses to determine

133 serologic and virologic status (SARS-CoV-2 anti-nucleoprotein [NP] serum antibodies [Elecsys<sup>®</sup>

134 Anti-SARS-CoV-2 assay; University of Washington, Seattle, WA, USA]; SARS-CoV-2 RT-PCR

135 [Abbott Real Time Quantitative SARS-CoV-2 assay; University of Washington, Seattle, WA,

136 USA]).

Reactogenicity (solicited AEs) data were documented by participants via an eDiary for 7
 days after dosing. Unsolicited treatment-emergent AEs (TEAEs) were collected through 28 days
 after each study dose; treatment-related MAAEs, AESI, SAEs, and death (any cause) were
 documented by study investigators through end of study.

141 2.4. Assessments

Serum was analyzed with validated assays for: nAbs specific to ancestral SARS-CoV-2 (via a
 microneutralization inhibitory concentration of 50% [MN<sub>50</sub>]; 360biolabs, Melbourne, Australia),<sup>12</sup>
 anti-rS IgG antibody levels via enzyme-linked immunosorbent assay (ELISA) as geometric
 mean ELISA units (GMEUs),<sup>13</sup> and hACE2 RBI antibodies to rS protein<sup>14</sup> (both assays; Novavax

medRxiv preprint doi: https://doi.org/10.1101/2024.11.07.24316930; this version posted November 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Clinical Immunology, Gaithersburg, MD, USA). Fit-for-purpose assays were used for anti-rS IgG
 and nAbs against variant strains (ie, BA.5, BQ.1.1).<sup>15</sup>

Solicited AEs were summarized by local/systemic symptom and maximum severity.
 Unsolicited AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA)
 version 25.0. AEs were categorized by severity and relationship to the study vaccine.

151 2.5. Statistical analyses

152 The per-protocol immunogenicity (PP-IMM) analysis sets for each dose included participants

with both a baseline (pre-dose) and ≥1 post-dose sample and no exclusionary protocol

violations. Participants with RT-PCR–positive nasal swabs and/or anti-NP seropositivity for

155 SARS-CoV-2 from baseline to day 35 and/or through 28 days after the 3<sup>rd</sup> or 4<sup>th</sup> study dose

were excluded from PP-IMM analyses. All statistical analyses were performed using SAS®

157 version 9.4 or higher (SAS Institute, Cary, NC).

158 Geometric means were defined as the antilog of the mean of the log-transformed values. Geometric mean fold rise (GMFR) was defined as the ratio of post-dose to pre-dose geometric 159 160 mean values within a study group. Data were summarized by trial vaccine group using 95% CI. 161 calculated based on the t-distribution of the log-transformed values for geometric means or 162 GMFR, then back-transformed to the original scale for presentation. For ratio calculations, concentration values below the lower limit of quantification (LLOQ) were replaced by  $0.5 \times$ 163 LLOQ. Seroconversion rate (SCR) was defined as a percentage of participants with a ≥4-fold 164 165 higher antibody level post versus pre-dose. The SCR 95% CIs were calculated using the exact 166 Clopper–Pearson method.

Noninferiority of the 3<sup>rd</sup>-dose response to that following the primary series was assessed by comparing the nAb titers 28 days after the 3<sup>rd</sup> dose with the response obtained 14 days after the primary series. To establish noninferiority, the following criteria were to be met: lower bound of two-sided 95% CI for the ratio of GMTs ( $GMT_{third}/GMT_{primary}$ ) >1.0 and lower bound of the two-

It is made available under a CC-BY-NC-ND 4.0 International license .

sided 95% CI for the difference of SCR (SCR<sub>third</sub>–SCR<sub>primary</sub>) >–10%. The 95% CI for SCR 171 172 difference was calculated using the Tango method. Serum samples from randomly selected 173 adult and adolescent PP-IMM subsets, who received all four doses, were used to assess immune responses against ancestral SARS-CoV-2 and variants at the specified time points. 174 175 The safety analysis sets included all participants who received ≥1 primary series study dose and were analyzed according to study material received; participants in the 3<sup>rd</sup>- and 4<sup>th</sup>-176 177 dose safety sets must have received these respective additional vaccinations. Reactogenicity 178 data are reported for participants in the safety analysis set with ≥1 eDiary entry for the associated dose. Safety data were summarized descriptively, and no statistical tests were 179 180 performed. Unsolicited AEs were reported by number and percentage, with corresponding exact 181 95% CI using the Clopper–Pearson method. 2.6. Ethical oversight 182 183 This study was performed in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and overseen by the NIAID DSMB. The protocol, 184 185 amendments, and overall oversight were provided by institutional review boards, research 186 ethics committees, and the National Institute of Allergy and Infectious Disease (NIAID) Data

187 Safety and Monitoring Board (DSMB), according to local regulations. Written informed consent

188 was received from all participants before enrollment.

## 189 3. Results

## 190 3.1. Study populations

Adult participants (N=29,943; screened from 27 December 2020 to 18 February 2021) were

- randomized to receive NVX-CoV2373 (N=19,961) or placebo (N=9982); 713 and 337
- 193 participants were included in the respective PP-IMM analysis sets (Figure 1A). After crossover,
- 194 226 and 160 adult participants were in the 3<sup>rd</sup>- and 4<sup>th</sup>-dose sets, respectively (**Figure 1B**). Of

It is made available under a CC-BY-NC-ND 4.0 International license .

195 2247 adolescent participants, 1491 and 756, respectively, were randomized to receive NVX-

196 CoV2373 and placebo (PP-IMM sets: 1126 and 537); there were 122 and 27 adolescent

197 participants analyzed for immunogenicity after the 3<sup>rd</sup> dose and 4<sup>th</sup> dose, respectively

198 (**Figure 1**).

Demographic characteristics were comparable among treatment arms within adult PP-IMM (**Table 1**) and safety (**Table S1**) sets, other than a higher proportion of 18- to 64-year-old participants in the adult PP-IMM set who received a  $3^{rd}$  dose, compared to other doses; characteristics were also comparable among treatment arms within the adolescent sets. Adult and adolescent participants received  $3^{rd}$  or  $4^{th}$  doses after a median of 6–12 months following the preceding dose (**Figure S1**).

3.2. Immunological responses to the ancestral strain in adults and adolescents

206 nAb (MN<sub>50</sub>) GMTs to the ancestral strain in adults rose from 11 to 1083 in the NVX-207 CoV2373 group (GMFR, 103 [95% CI, 92.4–115.6]) from day 0 to day 35 (Figure 2A). No 208 antibody response was detected in placebo-recipients from a baseline GMT of 10. Day 35 SCRs 209 were 94% with NVX-CoV2373 versus 2% with placebo. Additional doses of NVX-CoV2373 increased titers from pre-dose to 28 days post dose for both the 3<sup>rd</sup> and 4<sup>th</sup> doses, resulting in 210 211 nAb titers greater than those observed 14 days post primary series. Similar response trends were observed across doses of NVX-CoV2373 in the adolescent population (Figure 2B). 212 Noninferiority was achieved for the nAb response 28 days after the 3<sup>rd</sup> dose compared to 14 213 days after the primary series (GMTR and SCR difference) in both the adult and adolescent 214 populations (Figure 2C). 215 In adults, anti-rS IgG GMEUs rose from 119 to 49,384 in the NVX-CoV2373 group 216 (GMFR, 414 [368.8–464.2]) from day 0 to 35 versus no apparent change from day 0 (GMEU, 217

108) in the placebo group (GMFR, 1.2 [95% CI, 1.1–1.3]) (**Figure S2A**). GMEUs also

substantially increased from pre-dose to 28 days post 3<sup>rd</sup> and 4<sup>th</sup> doses. Adolescent participants

had low baseline GMEUs on day 0 and a robust increase on day 35 post active vaccination

It is made available under a CC-BY-NC-ND 4.0 International license .

221 (Figure S2B). Titers remained high with subsequent doses. hACE2 RBI GMTs followed a similar pattern as nAb and serum IgG responses in both adults (Figure S3A) and adolescents 222 223 (Figure S3B). Immunological responses after the primary series among participants regardless 224 of baseline serostatus were comparable to those in the baseline seronegative PP-IMM sets 225 across each of the assays (Figure S4). Durability of immunogenic response was assessed 4- and 8-months post 3<sup>rd</sup> dose in 226 227 subsets of the PP-IMM populations. Importantly, nAb, anti-rS IgG, and hACE2 RBI responses to the ancestral strain were preserved at levels comparable to those recorded 28 days after the 3<sup>rd</sup> 228

dose (**Figure S5**). Titers remained elevated from baseline and there were only minor declines in

230 GMFR and SCRs through 8 months post 3<sup>rd</sup> dose.

3.3. Immunological responses to the ancestral strain in adult age subgroups

232 Baseline nAb, serum IgG, and hACE2 RBI values were similar (within each assessment) 233 among participants aged 18 to <65 years and  $\geq$ 65 years in both treatment groups (**Table S2**). 234 Fourteen days after the primary series, the nAb titers in the NVX-CoV2373 group were ~1.4-fold higher in participants aged 18 to <65 years (123.8 [107.1-143.1]) compared with those aged 235 236 ≥65 years (86.1 [72.6–102.1]). Increases in serum IgG and hACE2 RBI titers on day 35 followed 237 a similar trend. SCRs from day 0 to day 35 for each of the response measures were comparable among the adult age groups. Immune responses in adults who received a 3<sup>rd</sup> and/or 4<sup>th</sup> dose of 238 239 NVX-CoV2373 were similar in younger and older adults (Table S3).

240 3.4. Cross-reactivity of NVX-CoV2373 against Omicron subvariants

nAb responses (ID<sub>50</sub>) to BA.5 and BQ.1.1 were assessed in a PP-IMM subset of adult
participants who received all four study doses of NVX-CoV2373. Fourteen days after the
primary series, responses that cross-reacted with variant strains were ~100-fold lower than
those against the ancestral strain; however, activity increased against each variant with
subsequent doses of NVX-CoV2373 (Figure 3A).

It is made available under a CC-BY-NC-ND 4.0 International license .

246	Cross-reactive serum anti-rS IgG responses were observed in adults against BA.5 and
247	BQ.1.1 after the primary series (~4-fold lower than against the ancestral virus) and subsequent
248	doses (~1.5-fold lower than those against ancestral virus; Figure 3B). Anti-rS IgG levels against
249	the ancestral strain and variants aligned with correlates of protection of >88% (based on day 35
250	anti-rS IgG levels and protection 56 days later), as described previously. <sup>16</sup> Anti-rS IgG
251	responses were also assessed based on positive or negative SARS-CoV-2 NP serostatus at
252	baseline, and a similar trend was observed as those described for the full immunogenicity
253	subset (Figure 3C).

3.5. Reactogenicity

Overall, solicited AEs were predominantly mild to moderate in severity and self-limited. Events 255 occurred at a somewhat higher frequency after the 3<sup>rd</sup> and 4<sup>th</sup> doses compared with the first two 256 257 doses (Figure 4A; Table S4). Solicited AEs were reported most frequently within 2 days after 258 vaccination and lasted a median 1–3 days; there were a limited number of AEs lasting >7 days 259 post injection (Table S5). Frequencies of solicited local AEs across doses trended similarly in 260 both the adult and adolescent study populations; following each dose, pain and tenderness 261 were the most common (>10%). Any solicited systemic AEs also occurred with similar frequency among the adult and adolescent study populations (Figure 4B; Table S4). Fatigue, headache, 262 malaise, and muscle pain were the most common (>40% for any dose) solicited systemic AEs 263 264 reported.

265 3.6. Unsolicited AEs

Through 28 days after the primary series, unsolicited AEs occurred at similar frequencies within the adult and adolescent populations in the NVX-CoV2373 (12.1% and 15.8%, respectively) and placebo (11.6% and 16.0%) groups (**Table S6**). Frequency of unsolicited AEs decreased with the 3<sup>rd</sup> and 4th doses of NVX-CoV2373 in both adults and adolescents. After the 4<sup>th</sup> dose, no adults and one (0.5%) adolescent participant had a vaccine-related AE (urticaria). Overall, there was minimal occurrence of vaccine-related or severe AEs, as well as MAAEs, SAEs, and

PIMMCs. During primary series follow-up, six adult participants discontinued the study for an unsolicited AE considered related to study vaccination. After unblinding, it was determined these were four and two participants in the active vaccine and placebo groups, respectively. At the data cutoff date, there were no unsolicited AEs leading to discontinuation in adolescent participants. No deaths during the study were considered related to vaccination, and there were no deaths in the adolescent population.

### 278 **4. Discussion**

These results expand on previous reports of the PREVENT-19 trial<sup>8,10</sup> and support phase 3 279 data<sup>17</sup> that demonstrated the safety and efficacy of two primary doses of NVX-CoV2373 in 280 adults and adolescents. Immunological responses to ancestral SARS-CoV-2 were markedly 281 increased 14 days after two primary doses of NVX-CoV2373 in participants serologically 282 283 negative for SARS-CoV-2 NP. Responses were durable, with continued robust humoral responses after a 3<sup>rd</sup> dose of NVX-CoV2373 and modest increases after a 4<sup>th</sup> dose. Over the full 284 period of the study, antibody titers were sustained in the range associated with a high degree of 285 protective efficacy.<sup>16</sup> Overall, NVX-CoV2373 was immunogenic in both younger and older adults 286 and adolescents and was well tolerated. 287

In both adults and adolescents, immunological response to a 3<sup>rd</sup> dose of NVX-CoV2373 288 289 was noninferior to that observed 14 days after the primary series. A median of 8 months after the 3<sup>rd</sup> dose, a 4<sup>th</sup> dose of NVX-CoV2373 resulted in elevated nAb titers comparable to those 290 post 3<sup>rd</sup> dose, and >4-fold higher than those observed 28-days post primary series. These 291 positive 3<sup>rd</sup>-dose responses are in line with those previously reported from a phase 2 trial.<sup>18</sup> nAb 292 titers before the 3<sup>rd</sup> and 4<sup>th</sup> doses were higher than those reported on Day 0, indicating response 293 durability. Notably, there was some decline in titers, indicative of waning immunity; however, this 294 can be expected as it would align with previously reported waning vaccine efficacy (to Delta 295 variants) >120 days post vaccination.<sup>19</sup> Although mRNA COVID-19 vaccines have generally 296

It is made available under a CC-BY-NC-ND 4.0 International license .

reported higher absolute post-vaccination IgG levels and neutralization titers, other studies have
 demonstrated significantly better persistence of response with NVX-CoV2373, with a slower
 decline in immune responses.<sup>20</sup> These data support the rationale for periodic reimmunization to
 help combat breakthrough infection in vaccinated individuals, especially with the frequent
 emergence of new variant strains.

302 Overall, AEs were mild to moderate and reactogenicity was generally transient. 303 Incidence and severity of local and systemic reactogenicity moderately increased following the  $2^{nd}$  dose and remained relatively consistent after both the  $3^{rd}$  dose and  $4^{th}$  dose. These findings 304 align with early studies during the pandemic where a COVID-19 vaccine primary series (ie, 305 mRNA, adenoviral vector, and protein-based) was observed to generally elicit higher 306 frequencies of reactogenic symptoms following the 2<sup>nd</sup> dose compared to the 1<sup>st</sup> dose.<sup>11,21,22</sup> 307 308 Side effects from COVID-19 vaccines have been identified as a driving force of vaccine hesitancy;<sup>23,24</sup> therefore, a key observation from this study may be that additional doses of NVX-309 310 CoV2373 in adult and adolescent populations did not further increase reactogenic symptom frequency. Here, unsolicited AE frequency after the primary series was comparable in the NVX-311 CoV2373 and placebo groups and incidence appeared to plateau after the 4<sup>th</sup> dose, which is 312 consistent with data from a phase 2 study conducted in Australia and the US.<sup>21</sup> Notably. the 313 solicited and unsolicited AE outcomes after repeat dosing with NVX-CoV2373 are reassuring for 314 315 future recommendations of additional doses of the Novavax COVID-19 vaccine, based on updated formulations that are expected due to continued SARS-CoV-2 strain circulation and 316 317 evolution.

A tolerable safety profile, immunogenicity, and protection from infection in older adults is of great interest for COVID-19 vaccines due to the higher risk of severe disease complications in those aged  $\geq$ 65 years.<sup>25</sup> No safety concerns were raised, and high and similar immune responses were observed across age groups; however, as expected, titers were lower in the older versus younger adult population, and titers were higher for the adolescent versus adult

It is made available under a CC-BY-NC-ND 4.0 International license .

323 populations. Notably, in both age groups, responses were within the range demonstrated to provide protective efficacy.<sup>16</sup> This is an important consideration, as real-world evidence 324 indicates that vaccine side effects are a key factor in selection of a specific vaccine formulation 325 326 when efficacy among the options is comparable.<sup>26</sup> Overall, the decision for use of a protein- or 327 mRNA-based vaccine formulation should consider patient characteristics/comorbidities and 328 individual preference (eq, vaccine hesitancy due to side effects), as well as immunogenicity. 329 Cross-protective humoral immune responses were observed against Omicron variants 330 BA.5 and BQ.1.1. Over time, SARS-CoV-2 lineages have evolved, attaining increased fitness 331 and immune evasion capabilities, compared to the ancestral strain and early Omicron variants. For example, additional mutations in the viral spike protein may promote improved replication in 332 respiratory cells, decreased affinity for ACE2, and antibody resistance.<sup>27</sup> A 3<sup>rd</sup> dose of 333 334 NVX-CoV2373 elicited a robust serum IgG response to BA.1 with an SCR comparable to that 335 observed after the primary series. These data are in line with those from a phase 2 study of a 336 smaller South African population, where elevated titers against BA.1 and BA.4/5 were observed after 3<sup>rd</sup> and 4<sup>th</sup> doses of NVX-CoV2373.<sup>28</sup> These immunogenicity results provide supportive 337 338 evidence for this protein-based vaccine platform's capacity to elicit broadly cross-reactive nAb titers against antigenically distant SARS-CoV-2 variant strains. 339

340 This study was conducted during the early years of what has become a continuously evolving epidemiology of SARS-CoV-2. At study initiation, virtually all participants were 341 infection-naive, and ancestral virus, as well as some early antigenically related variants, were 342 343 circulating. During the second year, more antigenically divergent variants emerged (eg, BA.1, BA.5, and BQ.1.1), reducing immunity among individuals vaccinated with authorized prototype 344 vaccines. This led to recommendations for "booster" doses of the prototype vaccine, followed by 345 346 updated vaccine formulations that targeted newer variants. For the 2023–2024 season, vaccines based on the XBB.1.5 variant became available.<sup>2,3</sup> JN.1, followed by strains within that 347 lineage (ie, KP.2 and KP.3), then became the dominant strains, and two mRNA-based vaccines 348

It is made available under a CC-BY-NC-ND 4.0 International license .

and the Novavax COVID-19 vaccine were authorized/approved as updated COVID-19 vaccines
for the 2024–2025 season.<sup>7</sup> In non-clinical models, the updated Novavax COVID-19 vaccine
(NVX-CoV2705 [JN.1]) generated broad cross-neutralizing responses against JN.1-lineage
subvariants, including KP.2 and KP.3.<sup>29</sup> The continued authorizations, preclinical data, and
assessments with convalescent serum samples suggest consistency for immunogenicity and
effectiveness of updated Novavax COVID-19 vaccines with this platform.

355 Immune responses described here demonstrate cross-reactivity of the prototype vaccine with genetic variants that had deviated from ancestral SARS-CoV-2. It can be expected that 356 immunogenicity of prototype vaccines would decline as new strains emerge and antigenic 357 distance grows. For example, based on genomic composition, early Omicron strains (eq, BA.1, 358 BA.5, and BQ.1) may be considered one antigenically related "family", followed by a larger shift 359 to XBB-related strains that are more antigenically distinct from ancestral SARS-CoV-2.<sup>30</sup> 360 Notably, within these 'antigenic families' of variants, cross-reactivity to updated vaccines may be 361 362 more likely.

363 A separate analysis of data from PREVENT-19 reported that nAb titers provide a correlate of protection for NVX-CoV2373 against ancestral virus,<sup>16</sup> and a more recent analysis<sup>19</sup> 364 confirmed antibody levels to the immune-evading Delta variant that support protective efficacy. 365 This vaccine platform also demonstrated cross-reactivity in the 2019nCoV-313/NCT05975060 366 367 study investigating an updated version of NVX-CoV2373 directed to XBB.1.5 (NVX-CoV2601), [in press], which was authorized for use in 2023–2024.<sup>2,3</sup> In that study, nAb responses to JN.1 368 and KP.2 were observed in previously vaccinated participants (≥3 doses of an mRNA-based 369 370 COVID-19 vaccine) who received one dose of NVX-CoV2601. Cross-reactivity against SARS-CoV-2 variants by vaccines generated using this platform may be related to unique platform 371 372 attributes, such as the saponin-based Matrix-M adjuvant and/or greater accessibility to highly conserved spike protein epitopes due to the truncated glycans of glycoproteins produced in the 373 baculovirus expression vector system.<sup>31</sup> Matrix-M adjuvant likely broadens epitope recognition<sup>32</sup> 374

It is made available under a CC-BY-NC-ND 4.0 International license .

- and elicits a Th1-dominant immune response capable of improving humoral immune
- <sup>376</sup> responses<sup>33</sup>. Despite the continued evolution of SARS-CoV-2, the ancestral vaccine and strain
- 377 responses analyzed in this study allow for the interpretation of cross-reactivity specific to this
- vaccine platform, which can provide insight into potential performance of updated vaccine
- 379 formulations against antigenically distant future-drifted strains.

## 380 **5. Conclusions**

- 381 In conclusion, NVX-CoV2373 elicited robust and durable humoral immune responses to
- 382 SARS-CoV-2, as well as cross-protective responses to key variants. Doses of NVX-CoV2373
- beyond the primary series induced spike-specific antibodies, with an acceptable reactogenicity
- profile. These results support continuing updates to this vaccine platform based on currently
- circulating strains to help effectively combat SARS-CoV-2 infection.

386

387

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 389 Acknowledgments

390 We especially thank each of the study participants who volunteered for this study, as well as the 2019nCoV-301 Study Group members.<sup>8,10</sup> We acknowledge the funders (BARDA and 391 392 NIAID/NIH), the members of the NIAID Data and Safety Monitoring Board (DSMB), community 393 leadership groups throughout the country who assisted with community engagement and 394 recruitment, unnamed colleagues at each of the sites who generously contributed to the trials in 395 many ways, and all unnamed colleagues at Novavax, Inc, who worked tirelessly and gave 396 unlimited efforts to the development, testing, and support of this trial. Medical writing support 397 was provided by Kelly Cameron, PhD, CMPP, Kelly M. Fahrbach, PhD, CMPP, with editorial support from Ebenezer M. Awuah-Yeboah, BS, all of Ashfield MedComms (New York, USA), an 398 Inizio company, supported by Novavax, Inc. 399

400 Appendix A: Supplementary data

401 Supplementary study results.

Funding: This work was supported by Novavax, Inc.; the Office of the Assistant Secretary for 402 403 Preparedness and Response, Biomedical Advanced Research and Development Authority 404 (BARDA: contract Operation Warp Speed: Novavax Project Agreement number 1 under Medical 405 CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium base agreement 406 no. 2020-530; Department of Defense no. W911QY20C0077); and the National Institute of 407 Allergy and Infectious Diseases (NIAID), National Institutes of Health. The NIAID provides grant 408 funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 409 Al68614), the HVTN Statistics and Data Management Center (UM1 Al68635), the HVTN 410 Laboratory Center (UM1 AI68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI68619), the AIDS Clinical Trials Group Leadership and Operations 411 412 Center (UM1 Al68636), and the Infectious Diseases Clinical Research Consortium leadership 413 group (UM1 AI148684).

It is made available under a CC-BY-NC-ND 4.0 International license .

414 **Data Statement:** Study details can be found at <u>https://clinicaltrials.gov/study/NCT04611802</u>.

Data that support the findings of this study are available in supplementary material and from the

416 corresponding author upon reasonable request.

## 417 **Declaration of Competing Interest**

418 Karen L. Kotloff reports financial support was provided by Novavax, Inc. and the National

419 Institute of Allergy and Infectious Diseases. Cynthia L. Gay reports financial support was

420 provided by National Institute of Allergy and Infectious Diseases. Alice McGarry, Wayne Woo,

421 Mingzhu Zhu, Shane Cloney-Clark, Joy Nelson, Haoua Dunbar, Miranda R. Cai, Iksung Cho,

422 Zhaohui Cai, Raj Kalkeri, Joyce S. Plested, Nita Patel, Katherine Smith, Anthony M. Marchese,

423 and Raburn M. Mallory report a relationship with Novavax, Inc. that includes: employment and

424 equity or stocks. German Anez reports a relationship with Novavax, Inc that includes:

425 employment (former) and equity or stocks. Gregory Glenn reports a relationship with Novavax,

426 Inc. that includes: consulting or advisory, employment (former), and equity or stocks. Lisa

427 Dunkle reports a relationship with Novavax, Inc. that includes: consulting or advisory,

428 employment (former), and equity or stocks. Karen L. Kotloff reports a relationship with Novavax,

429 Inc. that includes: funding grants. Medical writing support was funded by Novavax, Inc. If there

430 are other authors, they declare that they have no known competing financial interests or

431 personal relationships that could have appeared to influence the work reported in this paper.

## 432 Ethics Approval Statement

The study was performed in accordance with the International Conference on Harmonization

434 Good Clinical Practice guidelines and overseen by the NIAID Data Safety and Monitoring Board.

435 **Patient Consent Statement** 

436 All participants provided written informed consent before enrollment.

437

438

It is made available under a CC-BY-NC-ND 4.0 International license .

# 439 Author contributions

- 440 Germán Áñez: conceptualization, methodology, formal analysis, investigation, writing original draft
- 441 preparation, writing reviewing and editing
- 442 Alice McGarry: formal analysis, investigation, writing reviewing and editing
- 443 Wayne Woo: formal analysis, investigation, writing reviewing and editing
- 444 Karen L. Kotloff: data curation, investigation, writing reviewing and editing; resources
- 445 **Cynthia L. Gay**: data curation, investigation, writing reviewing and editing; resources
- 446 Mingzhu Zhu: writing reviewing and editing; resources
- 447 Shane Cloney-Clark: formal analysis, writing reviewing and editing
- 448 Joy Nelson: writing reviewing and editing; project administration
- 449 **Haoua Dunbar**: data curation, writing reviewing and editing
- 450 Miranda R. Cai: formal analysis, writing reviewing and editing
- 451 Iksung Cho: formal analysis, investigation, writing reviewing and editing, software
- 452 **Zhaohui Cai:** formal analysis, writing reviewing and editing
- 453 Raj Kalkeri: investigation, writing reviewing and editing
- 454 **Joyce S. Plested**: formal analysis, writing reviewing and editing
- 455 Nita Patel: resources, writing reviewing and editing
- 456 Katherine Smith: formal analysis, writing reviewing and editing
- 457 Anthony M. Marchese: writing updated draft preparation, writing reviewing and editing
- 458 Gregory M. Glenn: methodology, investigation, writing reviewing and editing
- 459 Raburn M. Mallory: methodology, formal analysis, writing reviewing and editing
- Lisa M. Dunkle: conceptualization, methodology, formal analysis, investigation, writing reviewing and
   editing, writing original draft preparation

462

463

It is made available under a CC-BY-NC-ND 4.0 International license .

### 465 **References**

- 466 1.COVID-19 Vaccine Tracker. Novavax: Nuvaxovid
- 467 <u>https://covid19.trackvaccines.org/vaccines/25/</u>. Accessed January 16, 2024.
- 468 2.Food and Drug Administration. Novavax COVID-19 Vaccine, Adjuvanted. Available online 17
   469 October 2023. <u>https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-</u>
   470 regulated-biologics/novavax-covid-19-vaccine-adjuvanted. Accessed January 31, 2024.
- 3.European Medicines Agency. Nuvaxovid. COVID-19 Vaccine (recombinant, adjuvanted).
   <u>https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid#ema-inpage-item-</u>
   product-info. Accessed February 1, 2024.
- 4.World Health Organization. Updated Risk Evaluation of JN.1, 15 April 2024.
  <u>https://www.who.int/docs/default-</u>
  <u>source/coronaviruse/15042024 jn1 ure.pdf?sfvrsn=8bd19a5c 7#:~:text=Effectiveness</u>
  2025f2(2025h e9(2025h e9(2025h))
- 477<u>%20of%20the%20XBB.,predicted%20to%20cross%2Drecognize%20BA</u>. Accessed May47813, 2024.
- 5.Link-Gelles R, Ciesla AA, Mak J, et al. Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults -Increasing Community Access to Testing Program, United States, September 2023-January 2024. *MMWR Morb Mortal Wkly Rep.* 2024;73(4):77-83.
- 484 6.U.S. Food and Drug Administration. Updated COVID-19 Vaccines for Use in the United States
   485 Beginning in Fall 2024 <u>https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-</u>
   486 vaccines-use-united-states-beginning-fall-2024. Accessed September 13, 2024.
- 7.U.S. Food and Drug Administration. COVID-19 Vaccines. <u>https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines</u>.
   Accessed September 25, 2024.
- 490 8.Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the
   491 United States and Mexico. *N Engl J Med.* 2022;386(6):531-543.
- 9.Marchese AM, Zhou X, Kinol J, et al. NVX-CoV2373 vaccine efficacy against hospitalization:
   A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
   Vaccine. 2023;41(22):3461-3466.
- 495 10.Anez G, Dunkle LM, Gay CL, et al. Safety, Immunogenicity, and Efficacy of the NVX 496 CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. JAMA Netw
   497 Open. 2023;6(4):e239135.
- 498 11.Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV 499 2 Vaccine. N Engl J Med. 2021;384(5):403-416.
- 12.Hamilton S, Zhu M, Cloney-Clark S, et al. Validation of a severe acute respiratory syndrome
   coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity. *J Virol Methods.* 2024;327:114945.
- 13.Zhu M, Cloney-Clark S, Feng SL, et al. A Severe Acute Respiratory Syndrome Coronavirus 2
   Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine
   Immunogenicity Using an Established Correlate of Protection. *Microorganisms*.
   2023;11(7).

- 14.Plested JS, Zhu M, Cloney-Clark S, et al. Severe Acute Respiratory Syndrome Coronavirus
   2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A
   Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
   *Microorganisms*. 2023;11(2).
- 15.Cai Z, Kalkeri R, Zhu M, et al. A Pseudovirus-Based Neutralization Assay for SARS-CoV-2
   Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for
   Vaccine Immunogenicity Evaluation. *Microorganisms*. 2024;12(3).
- 16.Fong Y, Huang Y, Benkeser D, et al. Immune correlates analysis of the PREVENT-19
   COVID-19 vaccine efficacy clinical trial. *Nat Commun.* 2023;14(1):331.
- 17.Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of the NVX-CoV2373
   Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. *Clin Infect Dis.* 2023;76(3):398-407.
- 18.Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a homologous
   booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a
   secondary analysis of a randomised, placebo-controlled, phase 2 trial. *Lancet Infect Dis.* 2022;22(11):1565-1576.
- 19.Follmann D, Mateja A, Fay MP, et al. Durability of Protection Against COVID-19 Through the
   Delta Surge for the NVX-CoV2373 Vaccine. *Clin Infect Dis.* 2024;79(1):78-85.
- 20.Liu X, Munro APS, Wright A, et al. Persistence of immune responses after heterologous and
   homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of
   the COV-BOOST trial. *J Infect.* 2023;87(1):18-26.
- 21.Alves K, Plested JS, Galbiati S, et al. Immunogenicity and safety of a fourth homologous
   dose of NVX-CoV2373. *Vaccine.* 2023;41(29):4280-4286.
- 22.Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid 19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615.
- 23.Al-Obaydi S, Hennrikus E, Mohammad N, Lehman EB, Thakur A, Al-Shaikhly T. Hesitancy
   and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with vaccine
   rollout in a multi-site healthcare system. *PLoS One.* 2022;17(8):e0272691.
- 24.Chrissian AA, Oyoyo UE, Patel P, et al. Impact of COVID-19 vaccine-associated side effects
   on health care worker absenteeism and future booster vaccination. *Vaccine*.
   2022;40(23):3174-3181.
- 538 25.Centers for Disease Control and Prevention. People With Certain Medical Conditions.
   539 <u>https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-</u>
   540 <u>medical-conditions.html</u>. Accessed January 31, 2024.
- 26.Salisbury D, Lazarus JV, Waite N, et al. COVID-19 Vaccine Preferences in General
   Populations in Canada, Germany, the United Kingdom, and the United States: Discrete
   Choice Experiment. *JMIR Public Health Surveill*. 2024;10:e57242.
- 27.Planas D, Staropoli I, Michel V, et al. Distinct evolution of SARS-CoV-2 Omicron XBB and
   BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. *Nat Commun.* 2024;15(1):2254.
- 28.Bhiman JN, Richardson SI, Lambson BE, et al. Novavax NVX-COV2373 triggers
   neutralization of Omicron sub-lineages. *Sci Rep.* 2023;13(1):1222.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 29.Walker R. Vaccines and Related Biological Products Advisory Committee. Novavax Data in
   Support of 2024-2025 Vaccine Update. June 5, 2024. Available at:
   https://www.fda.gov/media/179143/download. Accessed October 20, 2024.
- 30.Nextstrain.org. Genomic epidemiology of SARS-CoV-2 with subsampling focused globally
   since pandemic start. <u>https://nextstrain.org/ncov/gisaid/global/all-time?m=div</u>. Accessed
   August 12, 2024.
- 31.Wolff MW, Murhammer DW, Jarvis DL, Linhardt RJ. Electrophoretic analysis of glycoprotein
   glycans produced by lepidopteran insect cells infected with an immediate early
   recombinant baculovirus encoding mammalian beta1,4-galactosyltransferase. *Glycoconj* J. 1999;16(12):753-756.
- 32.Chung KY, Coyle EM, Jani D, et al. ISCOMATRIX adjuvant promotes epitope spreading and
   antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate
   with virus neutralization in humans. *Vaccine*. 2015;33(32):3953-3962.
- 33.Stertman L, Palm AE, Zarnegar B, et al. The Matrix-M adjuvant: A critical component of
- 563 vaccines for the 21(st) century. *Human vaccines & immunotherapeutics.*
- 564 2023;19(1):2189885.

 Table 1. Demographic characteristics (PP-IMM analysis sets).

	Adult main study				Pediatric expansion (12 to <18 years)			
	Primary series		3 <sup>rd</sup> Dose	4 <sup>th</sup> Dose	Primary series		3 <sup>rd</sup> Dose	4 <sup>th</sup> Dose
Characteristic	NVX-CoV2373 (n=713)	Placebo (n=337)	NVX-CoV2373 (n=226)	NVX-CoV2373 (n=160)	NVX-CoV2373 (n=1126)	Placebo (n=537)	NVX-CoV2373 (n=220)	NVX-CoV2373 (n=27)
Sex, n (%)						L		
Male	364 (51.1)	162 (48.1)	117 (51.8)	76 (47.5)	584 (51.9)	297 (55.3)	127 (57.7)	16 (59.3)
Female	349 (48.9)	175 (51.9)	109 (48.2)	84 (52.5)	542 (48.1)	240 (44.7)	93 (42.3)	11 (40.7)
Age (years)			1			L		It is
Mean (SD)	57.1 (15.69)	56.5 (16.81)	49.6 (14.17)	58.7 (13.89)	13.8 (1.39)	13.7 (1.42)	14.1 (1.51)	13.2 (1.22)
Median (range)	64.0 (18–95)	65.0 (18–85)	52.0 (19–79)	62.0 (19–84)	14.0 (12–17)	14.0 (12–17)	14.0 (12–17)	13.0 (12–17)
Age group (years), n (%)			1	I.		,	I.	Ivail
18–64	358 (50.2)	168 (49.9)	196 (86.7)	91 (56.9)	N/A	N/A	N/A	N/A ble
≥65	355 (49.8)	169 (50.1)	30 (13.3)	69 (43.1)	N/A	N/A	N/A	N/A ភ្
12 to <15	N/A	N/A	N/A	N/A	766 (68.0)	368 (68.5)	118 (53.6)	23 (85.2) <sup>Q</sup>
15 to <18	N/A	N/A	N/A	N/A	360 (32.0)	169 (31.5)	102 (46.4)	4 (14.8) <sup>ω</sup>
Region, n (%)			ļ	1		,	1	с ц
Mexico	48 (6.7)	23 (6.8)	0	0	0	0	0	0 🛓
United States	665 (93.3)	314 (93.2)	226 (100)	160 (100)	1126 (100)	537 (100)	220 (100)	27 (100) <mark>2</mark>
Race, n (%)			1			L		
White	571 (80.1)	257 (76.3)	187 (82.7)	134 (83.8)	866 (76.9)	402 (74.9)	186 (84.5)	22 (81.5) <mark>9</mark>
Black or African American	62 (8.7)	46 (13.6)	21 (9.3)	13 (8.1)	142 (12.6)	69 (12.8)	12 (5.5)	3 (11.1) at
Asian	19 (2.7)	14 (4.2)	13 (5.8)	6 (3.8)	34 (3.0)	23 (4.3)	7 (3.2)	0 0
American Indian or Alaska Native	8 (6.7)	16 (4.7)	1 (0.4)	5 (3.1)	13 (1.2)	6 (1.1)	1 (0.5)	0 licen
Mixed Origin	10 (1.4)	2 (0.6)	3 (1.3)	2 (1.3)	63 (5.6)	33 (6.1)	12 (5.5)	1 (3.7)
Native Hawaiian or Other Pacific Islander	0	1 (0.3)	1 (0.4)	0	3 (0.3)	1 (0.2)	1 (0.5)	0
Not Reported	3 (0.4)	1 (0.3)	0	0	5 (0.4)	3 (0.6)	1 (0.5)	1 (3.7)
Ethnicity, n (%)			1			L		
Hispanic or Latino	142 (19.9)	60 (17.8)	34 (15.0)	9 (5.6)	175 (15.5)	87 (16.2)	36 (16.4)	6 (22.2)
Not Hispanic or Latino	570 (79.9)	277 (82.2)	192 (85.0)	151 (94.4)	947 (84.1)	450 (83.8)	184 (83.6)	20 (74.1)
Not reported/unknown	1 (0.1)	0	0	0	4 (0.4)	0	0	1 (3.7)

SD, standard deviation. Note: Demographic and clinical characteristics are shown for the total PP-IMM set and were not developed for individual PP-IMM subsets.

It is made available under a CC-BY-NC-ND 4.0 International license .

## **Figure legends**

Figure 1. CONSORT diagram.

Participant enrollment and disposition for adult and adolescent populations. (A) Primary series and crossover. (B) Dose expansion.

Part of this figure was adapted from Añez G, et al. JAMA Netw Open. 2023;6(4):e239135.

\*Other reasons include receipt of another COVID-19 vaccine, noncompliance, investigator decision, incarceration, and pregnancy. <sup>†</sup>Participants could have more than one reason for exclusion. <sup>‡</sup>Participants with an immunogenicity sample after the 3rd dose were a combination of those who received 2 doses of NVX-CoV2373 in the initial series and those who received 2 doses during blinded crossover. <sup>§</sup>Three participants were excluded from the adult 4<sup>th</sup>-dose safety analysis set due to receipt of an external COVID-19 vaccine or an extra dose of NVX-CoV2373; three participants excluded from the adolescent PP-IMM set who received only 3 doses of NVX-CoV2373 are included in the 4<sup>th</sup>-dose safety analysis set.

**Figure 2.** nAb responses against the ancestral strain in PP-IMM analysis sets. A) Adults. B) Adolescents. C) Noninferiority comparison of nAb responses after the primary series and 3rd dose.

Baseline/pre-dose are defined as the last available assessment prior to administration of trial vaccine for the 1st, 3rd, or 4th dose. Post dose is 14 days (Day 35) after the primary series and 28 days after the 3rd or 4th dose. GMFR was calculated based on titer comparison of respective post vaccination and baseline samples for each group. SCR was calculated based on the number of participants with a ≥4-fold increase in antibody concentration from baseline divided by the number of participants with a sample collected at the designated post vaccination time. GMFR and SCR values with 95% CIs are noted. To establish noninferiority, the following criteria were to be met: lower bound (LB) of two-sided 95% CI for the ratio of GMTs (GMTthird/GMTprimary) >1.0; and LB of the two-sided 95% CI for the difference of SCR (GMTthird – GMTprimary) > -10%. Responses are compared 14 days (Day 35) after the primary series and 28 days after the 3rd dose. Criteria boundaries for 95% CI are marked with a dashed vertical line. GMT, geometric mean titer; LB, lower bound; nAb, neutralizing antibody; SCR, seroconversion rate.

**Figure 3.** Immunogenicity in an adult PP-IMM subset against the ancestral strain, BA.5, and BQ.1.1 before and after the primary series, 3<sup>rd</sup> dose, and 4<sup>th</sup> dose.

A) Pseudovirus neutralization assay (n=15 participants for each timepoint and strain).
B) Anti-rS IgG responses regardless of baseline SARS-CoV-2 serostatus (n=40 participants for each timepoint and strain, other than for 38 participants for 28 days after the 4<sup>th</sup> dose).
C) Anti-rS IgG responses by baseline SARS-CoV-2 serostatus (n=20 participants for each timepoint and strain, other than for 18 participants for 28 days after the 4<sup>th</sup> dose).
Fold differences compared with the ancestral strain for each series are shown in brackets.
GMFR are comparing GMTs from samples collected on the day of dosing (before vaccination) with samples collected 28 days after that same dose. CoP values in (B) were determined for the ancestral strain based on Day 35 anti-rS IgG levels with protection 56 days later (Fong et al 2022). CoP, correlate of protection; GMFR, geometric mean fold rise; GMT, geometric mean titer; SCR, seroconversion rate.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4. Reactogenicity within 7 days of each study dose.

Solicited (A) local and (B) systemic treatment-emergent adverse events were collected in adult (top) and adolescent (bottom) participants in the safety analysis sets with at least one eDiary entry. Note: There are no placebo reactogenicity data beyond the primary series as subsequent doses of placebo were not administered.

### Α





В

Pediatric expansion (12 to <18 years)

medRxiv preprint doi: https://doi.org/10.1101/2024. preprint (which was not certified by peer review) is lt is made .11.07.24316930; this version posted November 11, 2024. The copyright holder for this the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ble under a CC-BY-NC-ND 4.0 Inte license

It is made available under a CC-BY-NC-ND 4.0 International license .

**Figure 2.** Neutralizing antibody responses to the ancestral strain before and after the primary series, 3<sup>rd</sup>, and 4<sup>th</sup> doses (PP-IMM analysis sets).

## A. Adults



	3 aallaa	v	B.484		- BASA		
Participants, n	Baseline	Post dose	Pre dose	Post dose	Pre dose	Post dose	
NVX-CoV2373	710	708	223	223	160	180	
Placebo	334	336	NA	NA	NA	NA	

#### B. Adolescents



Primary series			3"	DOSS	मुव	4 <sup>u</sup> D098	
Participants, n	Baseline	Post dose	Pre dose	Post dose	Pre dose	Post dose	
NVX-CoV2373	485	436	62	62	27	27	
Placebo	136	134	NA	NA	NA	NA	

It is made available under a CC-BY-NC-ND 4.0 International license .

**C.** Noninferiority comparison of nAb responses after the primary series and 3<sup>rd</sup> dose.



Figure 3. Immunogenicity in an adult PP-IMM subset against the ancestral strain, BA.5, and BQ.1.1 before and after the primary series, 3<sup>rd</sup> dose, and 4<sup>th</sup> dose.

A) Pseudovirus neutralization assay (n=15 participants for each timepoint and strain).

B) Anti-rS IgG responses regardless of baseline SARS-CoV-2 serostatus (n=40 participants for each timepoint and strain, other than for 38 participants for 28 days after the 4<sup>th</sup> dose).

C) Anti-rS IgG responses by baseline SARS-CoV-2 serostatus (n=20 participants for each timepoint and strain, other than for 18 participants for 28 days after the 4<sup>th</sup> dose).

Fold differences compared to the ancestral strain for each series are shown with brackets. GMFR are comparing GMTs from samples collected on the day of dosing (before vaccination), to samples collected 28 days after that same dose. CoP in (B) were determined for the ancestral strain based on Day 35 anti-rS IgG levels with protection 56 days later (Fong et al 2022). CoP, correlate of protection; GMFR, geometric mean fold rise; GMT, geometric mean titer; SCR, seroconversion rate.





Figure 4. Proportion of participants with solicited (A) local and (B) systemic TEAEs within 7 days of each dose of NVX-CoV2373.

